Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, Investigation, Physical examination, Polymerase chain reaction
Clinical narrative: She was admitted for COVID-19; COVID-19; This is a literature report.  A 43-year-old female patient received BNT162b2 (BNT162B2), in Mar2021 as dose 1, single (Batch/Lot number: unknown), in Apr2021 as dose 2, single (Batch/Lot number: unknown) and in Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Lupus nephritis" (ongoing); "antiphospholipid syndrome" (ongoing), notes: prior stroke secondary; "chronic kidney disease stage 3" (unspecified if ongoing); "hypertension" (unspecified if ongoing); "pulmonary embolism" (unspecified if ongoing); "Stroke" (unspecified if ongoing); "hospitalization", start date: 17Jan2022 (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Hydroxychloroquine for Lupus nephritis, notes: 200 mg once daily; Mycophenolate mofetil for Lupus nephritis, notes: 360 mg twice daily; Sirolimus for Lupus nephritis, notes: 1 mg daily; Hydroxychloroquine for antiphospholipid syndrome, notes: 200 mg once daily; Mycophenolate mofetil for antiphospholipid syndrome, notes: 360 mg twice daily; Sirolimus for antiphospholipid syndrome, notes: 1 mg daily; Belimumab, start date: Mar2021, for Lupus nephritis, reaction(s): "diarrhea", notes: 800 mg weekly injections, this was stopped in July due to diarrhea and nausea; Belimumab, start date: Mar2021, for Lupus nephritis, reaction(s): "nausea", notes: 800 mg weekly injections, this was stopped in July due to diarrhea and nausea; Coumadin for antiphospholipid syndrome, notes: 2.5 mg daily. The following information was reported: DRUG INEFFECTIVE (hospitalization, medically significant), 285 min after the suspect product(s) administration, outcome "recovered", described as "She was admitted for COVID-19"; COVID-19 (hospitalization, medically significant), 285 min after the suspect product(s) administration, outcome "recovered". The patient was hospitalized for drug ineffective, covid-19 (start date: 17Jan2022, discharge date: Jan2022). The patient underwent the following laboratory tests and procedures: SLEDAI-2 K score: (Jun2020) 11; physical exam: (Jan2022) was most significant for dehydration; Polymerase chain reaction: (unspecified date) diagnosed with COVID-19 gastroenteritis; SARS-CoV-2 antibody test: (unspecified date) geater than 250, notes: elevated; Vital signs measurement: (Jan2022) within normal limits. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: She presented to the hospital on 17Jan2022 with a 2-day history of headache, cough, right collarbone pain, chills, fevers, chest pain, myalgias, fatigue, diarrhea, and generalized weakness. She was admitted for COVID-19 gastroenteritis diagnosed via PCR and a pre-renal acute kidney injury (AKI). She received IV fluids, two 6 mg doses of dexamethasone, and a 200 mg dose of Remdesivir. She improved significantly after two days and was discharged to follow up with her primary care provider and rheumatologist.; Sender's Comments: Based on the current available limited information in the case provided, the causal association between the events Drug ineffective and Covid-19 and the use of suspect product BNT162b2 cannot be fully excluded.,Linked Report(s) : US-PFIZER INC-202300148408 Same Article/drug/event; Different Patient;